CROI 2016 Program at a Glance

General Information

ABSTRACT PROCESS

General Information

Scientific Categories A. Virology

presentations, or rejected. Late-breaking abstract reviews included an assessment of the late-breaking nature of the work (versus just being a late submission). Common Reasons for Abstract Rejection • Information is not new enough • Methodology is inadequate or insufficient to support conclusions • Background does not summarize the hypothesis • Submission is poorly written • Abstract is duplicative of other submissions • Summary of essential results is inadequate or absent • Data are inadequate or insufficient to support conclusions • Submission reports clinical trial and data from unplanned analysis or incomplete or ongoing studies • Format does not follow guidelines (eg, section[s] missing, more than 1 graphic, table, or figure submitted) Statistics for Abstracts Total general abstract submitted. . . . . . . . . . . . .1936 Total general abstracts accepted. . . . . . . . . . . . . .951 General oral abstracts. . . . . . . . . . . . . . . . . 94 General poster abstracts. . . . . . . . . . . . . . . .857 Total late-breaking abstracts submitted. . . . . . . . . . 198 Total late-breaking abstracts accepted . . . . . . . . . . . 52 Late-breaking oral abstracts . . . . . . . . . . . . . . 25 Late-breaking poster abstracts. . . . . . . . . . . . . 27 All Authors on Accepted Abstracts Region N Percent Africa. . . . . . . . . . . . . . . . . . . . . . . . . 652 . . . . . . . . . . 13.5 Asia. . . . . . . . . . . . . .222 . . . . . . . . . . . 4.6 Australia. . . . . . . . . . . . 84 . . . . . . . . . . . 1.7 Europe . . . . . . . . . . . .1140 . . . . . . . . . . 22.7 Latin/South America. . . . . . . . . . . . . 77 . . . . . . . . . . . 1.6 North America. . . . . . . . .2644 . . . . . . . . . . 54.9 • Abstract is not appropriate for CROI • Controls are absent or inadequate • Statistical evaluation is inadequate or absent

B. Molecular Epidemiology and HIV/SIV Evolution C. Pathogenesis: Human Studies and Animal Models (D. Pathogenesis: Animal Models has been combined with Category C) E. Host Immune Responses to Infection,Vaccines, and Immunotherapy F. HIV Persistence, Reservoirs, Latency, Eradication, Including GeneTherapy G. Neuropathogenesis H. Clinical Pharmacology I. AntiretroviralTherapy: Preclinical Studies J. AntiretroviralTherapy: Randomized ClinicalTrials K. AntiretroviralTherapy: Observational Studies L. HIV Drug Resistance O. HIV-related and Non–HIV-Related Malignancies P. Cardiovascular Complications of HIV Infection and AntiretroviralTherapy Q. Other Complications of HIV Infection and AntiretroviralTherapy R. Tuberculosis and Other Opportunistic Infections S. Maternal/Fetal HIV T. Pediatrics and Adolescents U. Contraception and Reproductive and Sexual Health inWomen V. Prevention and Intervention Studies W. Epidemiology X. Implementation Science and Health Care Delivery Y. Population and Economic Modeling Abstract Content Author names, institutions, abstract titles, and abstracts in the Program and Abstracts eBook are generally presented as submitted by the corresponding author. Abstract Review Process The PC and a panel of volunteer external reviewers reviewed approximately 2000 submitted abstracts. Each abstract was reviewed by 5 to 10 reviewers selected for each abstract category based upon their individual expertise. PC members and external experts in the field reviewed the abstracts for the quality and originality of the work and scored them numerically. All reviewers were instructed to abstain from scoring any abstract on which they are an author or coauthor, have a financial or personal conflict of interest, or do not have the appropriate expertise to evaluate. Scores ranged from 1 (definite oral presentation) to 5 (rejected). Scores for each abstract were averaged and the standard deviation was calculated to assess variability. If variability was high, outlier scores are identified and censored. Abstracts with high variability in scores were discussed individually during a series of conference calls. Abstracts were accepted for oral presentations, for poster M. HIV Diagnostics N. HepatitisViruses

19

CROI 2016